108 related articles for article (PubMed ID: 12668017)
1. Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Miller WH; Manley PJ; Cousins RD; Erhard KF; Heerding DA; Kwon C; Ross ST; Samanen JM; Takata DT; Uzinskas IN; Yuan CC; Haltiwanger RC; Gress CJ; Lark MW; Hwang SM; James IE; Rieman DJ; Willette RN; Yue TL; Azzarano LM; Salyers KL; Smith BR; Ward KW; Johanson KO; Huffman WF
Bioorg Med Chem Lett; 2003 Apr; 13(8):1483-6. PubMed ID: 12668017
[TBL] [Abstract][Full Text] [Related]
2. Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis.
Anderson NA; Campos S; Butler S; Copley RCB; Duncan I; Harrison S; Le J; Maghames R; Pastor-Garcia A; Pritchard JM; Rowedder JE; Smith CE; Thomas J; Vitulli G; Macdonald SJF
J Med Chem; 2019 Oct; 62(19):8796-8808. PubMed ID: 31497959
[TBL] [Abstract][Full Text] [Related]
3. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Miller WH; Bondinell WE; Cousins RD; Erhard KF; Jakas DR; Keenan RM; Ku TW; Newlander KA; Ross ST; Haltiwanger RC; Bradbeer J; Drake FH; Gowen M; Hoffman SJ; Hwang SM; James IE; Lark MW; Lechowska B; Rieman DJ; Stroup GB; Vasko-Moser JA; Zembryki DL; Azzarano LM; Adams PC; Huffman WF
Bioorg Med Chem Lett; 1999 Jul; 9(13):1807-12. PubMed ID: 10406646
[TBL] [Abstract][Full Text] [Related]
4. Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Studies implicating transporter-mediated intestinal secretion.
Ward KW; Hardy LB; Kehler JR; Azzarano LM; Smith BR
Xenobiotica; 2004 Apr; 34(4):367-77. PubMed ID: 15268981
[TBL] [Abstract][Full Text] [Related]
5. Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.
Coleman PJ; Askew BC; Hutchinson JH; Whitman DB; Perkins JJ; Hartman GD; Rodan GA; Leu CT; Prueksaritanont T; Fernandez-Metzler C; Merkle KM; Lynch R; Lynch JJ; Rodan SB; Duggan ME
Bioorg Med Chem Lett; 2002 Sep; 12(17):2463-5. PubMed ID: 12161158
[TBL] [Abstract][Full Text] [Related]
6. Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.
Keenan RM; Miller WH; Barton LS; Bondinell WE; Cousins RD; Eppley DF; Hwang SM; Kwon C; Lago MA; Nguyen TT; Smith BR; Uzinskas IN; Yuan CC
Bioorg Med Chem Lett; 1999 Jul; 9(13):1801-6. PubMed ID: 10406645
[TBL] [Abstract][Full Text] [Related]
7. Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.
Vianello P; Cozzi P; Galvani A; Meroni M; Varasi M; Volpi D; Bandiera T
Bioorg Med Chem Lett; 2004 Feb; 14(3):657-61. PubMed ID: 14741263
[TBL] [Abstract][Full Text] [Related]
8. [Advances in the study of the integrin alpha(v) beta3 antagonists].
Ni GH; Jiang FC
Yao Xue Xue Bao; 2006 Jul; 41(7):577-82. PubMed ID: 17007346
[No Abstract] [Full Text] [Related]
9. Adhesion and migration of extracellular matrix-stimulated breast cancer.
Bartsch JE; Staren ED; Appert HE
J Surg Res; 2003 Mar; 110(1):287-94. PubMed ID: 12697413
[TBL] [Abstract][Full Text] [Related]
10. Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
De Corte BL; Kinney WA; Liu L; Ghosh S; Brunner L; Hoekstra WJ; Santulli RJ; Tuman RW; Baker J; Burns C; Proost JC; Tounge BA; Damiano BP; Maryanoff BE; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2004 Oct; 14(20):5227-32. PubMed ID: 15380233
[TBL] [Abstract][Full Text] [Related]
11. Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations.
Ward KW; Azzarano LM; Evans CA; Smith BR
Xenobiotica; 2004 Apr; 34(4):353-66. PubMed ID: 15268980
[TBL] [Abstract][Full Text] [Related]
12. 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.
Ghosh S; Santulli RJ; Kinney WA; Decorte BL; Liu L; Lewis JM; Proost JC; Leo GC; Masucci J; Hageman WE; Thompson AS; Chen I; Kawahama R; Tuman RW; Galemmo RA; Johnson DL; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2004 Dec; 14(23):5937-41. PubMed ID: 15501072
[TBL] [Abstract][Full Text] [Related]
13. Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.
Perron-Sierra F; Saint Dizier D; Bertrand M; Genton A; Tucker GC; Casara P
Bioorg Med Chem Lett; 2002 Nov; 12(22):3291-6. PubMed ID: 12392735
[TBL] [Abstract][Full Text] [Related]
14. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
[TBL] [Abstract][Full Text] [Related]
15. New potent αvβ3 integrin ligands based on azabicycloalkane (γ,α)-dipeptide mimics.
Pilkington-Miksa M; Araldi EM; Arosio D; Belvisi L; Civera M; Manzoni L
Org Biomol Chem; 2016 Mar; 14(12):3221-33. PubMed ID: 26917057
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
Wendt JA; Wu H; Stenmark HG; Boys ML; Downs VL; Penning TD; Chen BB; Wang Y; Duffin T; Finn MB; Keene JL; Engleman VW; Freeman SK; Hanneke ML; Shannon KE; Nickols MA; Steininger CN; Westlin M; Klover JA; Westlin W; Nickols GA; Russell MA
Bioorg Med Chem Lett; 2006 Feb; 16(4):845-9. PubMed ID: 16303301
[TBL] [Abstract][Full Text] [Related]
17. Tricyclic pharmacophore-based molecules as novel integrin alphavbeta3 antagonists. Part IV: preliminary control of alphavbeta3 selectivity by meta-oriented substitution.
Kubota D; Ishikawa M; Ishikawa M; Yahata N; Murakami S; Fujishima K; Kitakaze M; Ajito K
Bioorg Med Chem; 2006 Jun; 14(12):4158-81. PubMed ID: 16504518
[TBL] [Abstract][Full Text] [Related]
18. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
Beck V; Herold H; Benge A; Luber B; Hutzler P; Tschesche H; Kessler H; Schmitt M; Geppert HG; Reuning U
Int J Biochem Cell Biol; 2005 Mar; 37(3):590-603. PubMed ID: 15618016
[TBL] [Abstract][Full Text] [Related]
19. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro.
Patsenker E; Popov Y; Wiesner M; Goodman SL; Schuppan D
J Hepatol; 2007 May; 46(5):878-87. PubMed ID: 17258347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
